HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

balicatib

cathepsin K inhibitor

Also Known As:

N-(1-((cyanomethyl)carbamoyl)cyclohexyl)-4-(4-propylpiperazin-1-yl)benzamide

Networked: 5 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Adami, Silvano: 2 articles (03/2012 - 07/2008)
2.	Gamse, R: 2 articles (01/2012 - 12/2011)
3.	Jerome, C: 2 articles (01/2012 - 12/2011)
4.	Missbach, M: 2 articles (01/2012 - 12/2011)
5.	Duong, Le T: 1 article (04/2016)
6.	Langdahl, Bente: 1 article (04/2016)
7.	Leung, Albert T: 1 article (04/2016)
8.	Benhamou, Claude-Laurent: 1 article (03/2012)
9.	Czerwiński, Edward: 1 article (03/2012)
10.	Farrerons, Jordi: 1 article (03/2012)

Related Diseases

1.	Osteoporosis 07/01/2008 - "We report the case of an adult white woman, enrolled in a double-blind, placebo-controlled, multicentric trial evaluating the efficacy and safety of the cathepsin K inhibitor balicatib for osteoporosis. " 03/01/2012 - "In a multicenter clinical trial in North America and Europe that tested the cathepsin K (catK) inhibitor balicatib for the treatment of osteoporosis, several patients developed hardening of the skin. " 01/01/2012 - "Balicatib, an inhibitor of the osteoclastic enzyme cathepsin K, was tested in ovariectomized monkeys, a model for osteoporosis. " 12/01/2011 - "Balicatib, an inhibitor of the osteoclastic enzyme cathepsin K, was tested in ovariectomized monkeys, a model for osteoporosis. "
2.	Localized Scleroderma (Morphea) 03/01/2012 - "Nine patients of 709 treated with balicatib developed skin hardening and were given a diagnosis of morphea-like skin changes. " 07/01/2008 - "Drug-induced morphea: report of a case induced by balicatib and review of the literature." 03/01/2012 - "Morphea-like skin reactions in patients treated with the cathepsin K inhibitor balicatib."
3.	Postmenopausal Osteoporosis 04/01/2016 - "Several CatK inhibitors, including relacatib, balicatib, odanacatib and ONO-5334 had entered clinical development for metabolic bone disorders with increased bone resorption, such as postmenopausal osteoporosis. "
4.	Fibrosis (Cirrhosis) 03/01/2012 - "It is therefore plausible that the observed dermal fibrosis in balicatib-treated patients is a result of impaired degradation of extracellular matrix proteins and may represent a class effect of catK inhibitors. "
5.	Bone Resorption 04/01/2016 - "Several CatK inhibitors, including relacatib, balicatib, odanacatib and ONO-5334 had entered clinical development for metabolic bone disorders with increased bone resorption, such as postmenopausal osteoporosis. "

Related Drugs and Biologics

1.	Cathepsin K
2.	Enzymes
3.	Extracellular Matrix Proteins
4.	ONO-5334
5.	odanacatib
6.	relacatib